Related Experiment Video

Updated: Jul 1, 2026

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection
12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

43.2K

SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies

Yury Valdes-Balbin1, Darielys Santana-Mederos1, Lauren Quintero1

  • 1Finlay Vaccine Institute, 200 and 21 Street, Havana 11600, Cuba.

ACS Chemical Biology
|July 5, 2021
PubMed

Insights

Developing a COVID-19 vaccine using recombinant receptor binding domain (RBD) conjugated to tetanus toxoid (TT) induced a potent immune response in animals. This conjugate vaccine candidate, SOBERANA02, shows promise for clinical evaluation and future antiviral vaccine development.

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • The COVID-19 pandemic necessitates rapid vaccine development.
  • Neutralizing antibodies targeting the viral spike glycoprotein's receptor binding domain (RBD) are crucial for vaccine efficacy.
  • Immune responses to the RBD correlate with viral neutralization.

Purpose of the Study:

  • To evaluate the immunogenicity of recombinant RBD conjugated to tetanus toxoid (TT) as a COVID-19 vaccine candidate.
  • To assess the quality and durability of the immune response induced by the RBD-TT conjugate.

Main Methods:

  • Development of macromolecular constructs with recombinant RBD conjugated to TT.
  • Immunization of laboratory animals with the RBD-TT conjugate vaccine candidate.
  • Analysis of the immune response, including antibody levels, affinity maturation, and B-memory cell generation.

Main Results:

  • RBD-TT conjugates induced a potent immune response in laboratory animals.
  • The immunization resulted in a predominant IgG immune response.
  • Evidence of affinity maturation and long-term specific B-memory cells was observed.

Conclusions:

  • The RBD-TT conjugate vaccine candidate (SOBERANA02) demonstrates significant potential for clinical evaluation.
  • This approach paves the way for developing other conjugate vaccines against viral infections.
  • Conjugate vaccine strategies can elicit robust and durable immune responses against SARS-CoV-2.

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.2K
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency09:04

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency

Published on: May 11, 2020

12.9K

Related Concept Videos

Cross-reactivity00:42

Cross-reactivity

Overview
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
Rabies01:28

Rabies

Rabies is a lethal zoonotic disease caused by a single-stranded, negative-sense RNA virus of the Lyssavirus genus, within the family Rhabdoviridae. Its primary mode of transmission to humans is through bites or saliva-contaminated scratches from infected mammals such as dogs, bats, raccoons, or foxes. Transmission can also occur if infectious saliva contacts abraded skin or intact mucous membranes, including the conjunctiva.Viral Entry and Early ReplicationOnce introduced at the bite or scratch...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...